Contextualizing the Development of Anti-HER2 Therapies for Patients with Advanced Urothelial Carcinoma

Key Points

• Advanced urothelial carcinoma shows promise with emerging anti-HER2 therapies, enhancing patient care.
• Significant improvements in clinical outcomes noted for patients treated with these targeted therapies.
• Comprehensive review of therapeutic development highlights the vital role of biomarkers for patient stratification.
• Implications call for further research to validate these therapies and explore combination treatments.